PD-L1/2 expression in solid tumors inhibits chimeric antigen receptor (CAR) T-cell efficacy. A PD-1 dominant negative receptor expressed in CAR T cells provides cell-intrinsic checkpoint blockade and augments antitumor efficacy. A combinatorial immunotherapeutic strategy of combining CAR T cells with checkpoint blockade is a promising treatment approach for solid tumors.
Author Info: (1) Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New Yor
Author Info: (1) Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. (2) Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. (3) Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, NY, USA. (4) Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
